生血宁治疗维持性血液透析患者肾性贫血及改善铁代谢的临床观察

Clinical observation of Shengxuening tablets in maintenance hemodialysis patients with renal anemia and improve iron metabolism of blood

目的观察生血宁治疗尿毒症维持性血液透析患者肾性贫血的临床疗效。方法采用随机对照方法将维持性血液透析合并肾性贫血患者50例随机分为治疗组和对照组，其中治疗组25例，对照组25例。对照组予常规治疗，治疗组在常规治疗的基础上加用生血宁0．5g，一天3次，疗程3个月，并于观察结束时分别检测血红蛋白、红细胞计数、红细胞压积、血清铁、血清铁蛋白水平。2组治疗期间均使用重组人促红细胞生成素50～100IU／kg，每周2～3次。结果治疗前治疗组与对照组在血红蛋白、红细胞计数、红细胞压积、血清铁、血清铁蛋白上比较，无统计学差异（P〉0．05），具有可比性。治疗后2组在血红蛋白、红细胞计数、红细胞压积方面比较，治疗组平均水平均略高于对照组，但组间比较无统计学差异（P〉0．05），可能与2组患者均使用促红细胞生成素治疗、改善了维持性血液透析患者的贫血状况所致。治疗组在血清铁蛋白、血清铁上升的平均水平高于对照组，比较有统计学差异（P〈0．05）。结论生血宁能够改善维持性血液透析患者缺铁性贫血状态，提高患者红蛋白、红细胞计数、红细胞压积，促进铁转运及利用，增加储备铁，降低铁耗竭，改善铁代谢。

Objective To observe the efficacy of Shengxuening tablets in the treatment of maintenance hemodialysis patients with renal anemia. Methods Fifty patients were divided into treatment group and control group, with 25cases in each group. , control group received conventional therapy, treatment group, patients in treatment group were given conventional therapy combined with Shengxuening 0. 5 g orally,3 time/d for treatment. Treated for 3 months, to observe the treatment effects of the two groups, assessment[hemoglobin, hematokrit （HCT）, red blood cell count, serum iron, serum ferritin]before treatment and after treatment. All patients receied recombinant human erythropoietin 50-100IU/kg, 2-3 times per week, Results There were not statistically significant difference between treatment group and control group in hemoglobin, hematokrit, red blood cell count,Serum iron, serum ferritin before treatment（P〈0. 05）, which meant comparable. After treatment, the treatment group was slightly higher than the control group in the aspects of hemoglobin, hematokrit, red blood celt count. But there were no statistically significant difference between groups（P〈0. 05）, it may be attributed to two groups of patients using erythropoietin treatment, which improve the anemia status in maintenance hemodialysis patients. The average level of serum iron and serum ferritin in the treatment group was higher than that in the control group with statistically significant differences（P〈0. 05）. Conclusions Shengxuening tablets can improve maintenance hemodialysis patients with iron deficiency anemia status, improve patients with hemoglobin, red blood cell count, hematocrit, promote iron transport and utilization, increase the iron reserves, reduce iron depletion, improve iron metabolism clinical efficacy.